Lee Ching Lew

Elena Lew Lee Ching is the Executive Director at ProBionic Corp., a Korea-based microbiome biotech company specializing in the discovery, development, and global commercialization of probiotic and postbiotic solutions. With a strong foundation in microbiology and regulatory strategy, she bridges science and business to bring clinically supported microbiome innovations to market. Her work focuses on translating proprietary strains—such as Lactobacillus sakei Probio65 and Lactobacillus plantarum Probio87—into scalable applications across skin health, immune modulation, women’s health, and respiratory wellness. She actively leads international partnerships, regulatory submissions, and commercialization strategies across Asia, Europe, and North America. Elena is deeply involved in global market expansion, including negotiations with multinational partners, regulatory compliance (EFSA, FDA, MFDS), and clinical development initiatives. She is also driving long-term strategy toward microbiome-based therapeutics, including live biotherapeutic products (LBP) for chronic conditions. Passionate about science-backed innovation, Elena is committed to advancing the role of the microbiome in next-generation health solutions while building strategic collaborations worldwide.